Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management

Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with var...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Igor G. Bakulin, Maria I. Skalinskaya, Igor V. Maev, Ekaterina V. Skazyvaeva, Mariia S. Zhuravleva, Larisa B. Gaikovaya, Natalia V. Bakulina, Aleksei I. Ermakov, Ekaterina S. Alekseenko, Kristina N. Ivanova, Mikhail V. Solovev
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	inflammatory bowel diseases crohn’s disease ulcerative colitis safety of inflammatory bowel diseases therapy efficacy of inflammatory bowel diseases therapy 5-aminosalicylates thiopurines biologic therapy Medicine R
Acceso en línea:	https://doaj.org/article/b1259293af26444085a9d53cbce6157d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1259293af26444085a9d53cbce6157d
record_format	dspace
spelling	oai:doaj.org-article:b1259293af26444085a9d53cbce6157d2021-12-01T12:22:36ZPharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management0040-36602309-534210.26442/00403660.2021.08.200982https://doaj.org/article/b1259293af26444085a9d53cbce6157d2021-08-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/79366/60028https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.Igor G. BakulinMaria I. SkalinskayaIgor V. MaevEkaterina V. SkazyvaevaMariia S. ZhuravlevaLarisa B. GaikovayaNatalia V. BakulinaAleksei I. ErmakovEkaterina S. AlekseenkoKristina N. IvanovaMikhail V. Solovev"Consilium Medicum" Publishing housearticleinflammatory bowel diseasescrohn’s diseaseulcerative colitissafety of inflammatory bowel diseases therapyefficacy of inflammatory bowel diseases therapy5-aminosalicylatesthiopurinesbiologic therapyMedicineRRUТерапевтический архив, Vol 93, Iss 8, Pp 841-852 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	inflammatory bowel diseases crohn’s disease ulcerative colitis safety of inflammatory bowel diseases therapy efficacy of inflammatory bowel diseases therapy 5-aminosalicylates thiopurines biologic therapy Medicine R
spellingShingle	inflammatory bowel diseases crohn’s disease ulcerative colitis safety of inflammatory bowel diseases therapy efficacy of inflammatory bowel diseases therapy 5-aminosalicylates thiopurines biologic therapy Medicine R Igor G. Bakulin Maria I. Skalinskaya Igor V. Maev Ekaterina V. Skazyvaeva Mariia S. Zhuravleva Larisa B. Gaikovaya Natalia V. Bakulina Aleksei I. Ermakov Ekaterina S. Alekseenko Kristina N. Ivanova Mikhail V. Solovev Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
description	Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.
format	article
author	Igor G. Bakulin Maria I. Skalinskaya Igor V. Maev Ekaterina V. Skazyvaeva Mariia S. Zhuravleva Larisa B. Gaikovaya Natalia V. Bakulina Aleksei I. Ermakov Ekaterina S. Alekseenko Kristina N. Ivanova Mikhail V. Solovev
author_facet	Igor G. Bakulin Maria I. Skalinskaya Igor V. Maev Ekaterina V. Skazyvaeva Mariia S. Zhuravleva Larisa B. Gaikovaya Natalia V. Bakulina Aleksei I. Ermakov Ekaterina S. Alekseenko Kristina N. Ivanova Mikhail V. Solovev
author_sort	Igor G. Bakulin
title	Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
title_short	Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
title_full	Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
title_fullStr	Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
title_full_unstemmed	Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
title_sort	pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/b1259293af26444085a9d53cbce6157d
work_keys_str_mv	AT igorgbakulin pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT mariaiskalinskaya pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT igorvmaev pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT ekaterinavskazyvaeva pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT mariiaszhuravleva pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT larisabgaikovaya pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT nataliavbakulina pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT alekseiiermakov pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT ekaterinasalekseenko pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT kristinanivanova pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement AT mikhailvsolovev pharmacotherapyofinflammatoryboweldiseasesefficacyperformanceandsafetymanagement
_version_	1718405194292658176

Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management

Ejemplares similares